autologous IL-12/multi-targeted primed T cells RPTR 168
A preparation of genetically modified, multi-antigen-targeted autologous T lymphocytes, tethered with the human immunostimulatory cytokine interleukin-12 (IL-12), with potential immunostimulating and antineoplastic activities. RPTR 168 is prepared from monocyte-derived dendritic cells (moDCs) that are pulsed with five tumor-associated antigens (TAAs) to expand cytotoxic T lymphocytes (CTLs) that are subsequently loaded with IL-12. Upon administration, the autologous IL-12/multi-targeted primed T cells RPTR 168 specifically target tumor cells expressing the five TAAs, which lead to a specific cytotoxic T-lymphocyte (CTL)-mediated killing of these tumor cells. In addition, IL-12 expression activates the immune system by promoting the secretion of interferon-gamma (IFN-g), activating natural killer cells (NKs), and inducing CTL responses, which may further increase tumor cell death and decrease tumor cell proliferation.
Synonym: | autologous IL-12-expressing MTC RPTR 168 autologous IL-12/multi-targeted primed T lymphocytes RPTR 168 PRIME IL-12 |
---|---|
Code name: | RPTR 168 RPTR-168 RPTR168 |